1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. T-CELL IMMUNOTHERAPY MARKET BY TECHNOLOGY
5.1. Introduction
5.2. CAR-T cell therapy
5.3. TCR (T-cell receptor) therapy
5.4. Tumor-infiltrating lymphocyte (TIL) therapy
5.5. In vivo T-cell engineering platforms
6. T-CELL IMMUNOTHERAPY MARKET BY INDICATION/APPLICATION
6.1. Introduction
6.2. Hematologic malignancies
6.3. Multiple myeloma
6.4. Solid tumors
6.5. Other oncologic indications
7. T-CELL IMMUNOTHERAPY MARKET BY END-USER
7.1. Introduction
7.2. Hospitals & specialized infusion centers
7.3. Academic medical centers
7.4. Outpatient oncology clinics
7.5. Contract manufacturing organizations (CMOs)/IDMOs
7.6. Diagnostic laboratories
8. T-CELL IMMUNOTHERAPY MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Technology
8.2.2. By Indication/Application
8.2.3. By End-User
8.2.4. By Country
8.2.4.1. United States
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Technology
8.3.2. By Indication/Application
8.3.3. By End-User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Technology
8.4.2. By Indication/Application
8.4.3. By End-User
8.4.4. By Country
8.4.4.1. United Kingdom
8.4.4.2. Germany
8.4.4.3. France
8.4.4.4. Italy
8.4.4.5. Spain
8.4.4.6. Others
8.5. Middle East & Africa
8.5.1. By Technology
8.5.2. By Indication/Application
8.5.3. By End-User
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. UAE
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. By Technology
8.6.2. By Indication/Application
8.6.3. By End-User
8.6.4. By Country
8.6.4.1. Japan
8.6.4.2. China
8.6.4.3. India
8.6.4.4. South Korea
8.6.4.5. Taiwan
8.6.4.6. Indonesia
8.6.4.7. Thailand
8.6.4.8. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Cellular Biomedicine Group
10.2. Autolus Novartis
10.3. Gilead Sciences, Inc
10.4. Adaptimmune Therapeutics
10.5. Cellectis
10.6. Bluebird bio
10.7. Immunocore
10.8. Innovative Cellular Therapeutics
10.9. Iovance Biotherapeutics
10.10. Celgene
11. RESEARCH METHODOLOGY
LIST OF FIGURES
LIST OF TABLES